Exploring the Ribose Sub-Pocket of the Substrate-Binding Site in Escherichia coli IspE: Structure-Based Design, Synthesis, and Biological Evaluation of Cytosines and Cytosine Analogues
暂无分享,去创建一个
F. Diederich | A. Bacher | M. Fischer | A. Hirsch | B. Illarionov | Shoichi Osawa | B. Bernet | Andri Schütz | J. Mathis | Andri P Schütz
[1] F. Diederich,et al. Cycloalkane and alicyclic heterocycle complexation by new switchable resorcin[4]arene-based container molecules: NMR and ITC binding studies. , 2011, Chemistry.
[2] W. Eisenreich,et al. Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr). , 2011, Journal of medicinal chemistry.
[3] T. Carell,et al. 5‐Hydroxymethylcytosin, die sechste Base des Genoms , 2011 .
[4] W. Eisenreich,et al. Biochemistry of the non-mevalonate isoprenoid pathway , 2011, Cellular and Molecular Life Sciences.
[5] L. Salonen,et al. Aromatische Ringe in chemischer und biologischer Erkennung: Energien und Strukturen , 2011 .
[6] D. Roos,et al. Fosmidomycin Uptake into Plasmodium and Babesia-Infected Erythrocytes Is Facilitated by Parasite-Induced New Permeability Pathways , 2011, PloS one.
[7] Xuehui Chen,et al. Crystal structure of 4‐diphosphocytidyl‐2‐C‐methyl‐D‐erythritol kinase (IspE) from Mycobacterium tuberculosis , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] H. Schwalbe,et al. NMR Studies of DOXP Reductoisomerase and its Inhibitor Complex , 2011, Chembiochem : a European journal of chemical biology.
[9] P. T. Kaye,et al. Synthesis and evaluation of phosphonated N-heteroarylcarboxamides as DOXP-reductoisomerase (DXR) inhibitors. , 2011, Bioorganic & medicinal chemistry.
[10] F. Hanser,et al. Single-Beat Noninvasive Imaging of Ventricular Endocardial and Epicardial Activation in Patients Undergoing CRT , 2011, PloS one.
[11] W. Eisenreich,et al. Biosynthesis of isoprenoids: crystal structure of the [4Fe-4S] cluster protein IspG. , 2010, Journal of molecular biology.
[12] J. Hoebeke,et al. Mechanisms of genetically-based resistance to malaria. , 2010, Gene.
[13] Danny Reinberg,et al. Molecular Signals of Epigenetic States , 2010, Science.
[14] W. Reik,et al. Epigenetic Reprogramming in Plant and Animal Development , 2010, Science.
[15] C. Wongsrichanalai,et al. Extensive Drug Resistance in Malaria and Tuberculosis , 2010, Emerging infectious diseases.
[16] M. Rohmer,et al. Isoprenoid biosynthesis via the methylerythritol phosphate pathway: structural variations around phosphonate anchor and spacer of fosmidomycin, a potent inhibitor of deoxyxylulose phosphate reductoisomerase. , 2010, The Journal of organic chemistry.
[17] W. Eisenreich,et al. Probing the reaction mechanism of IspH protein by x-ray structure analysis , 2009, Proceedings of the National Academy of Sciences.
[18] S. Abdulla,et al. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children , 2009, Malaria Journal.
[19] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.
[20] A. Dicko,et al. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial , 2009, Malaria Journal.
[21] N. Day,et al. Plasmodium falciparum pfmdr1 Amplification, Mefloquine Resistance, and Parasite Fitness , 2009, Antimicrobial Agents and Chemotherapy.
[22] E. Oldfield,et al. Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. , 2008, Journal of the American Chemical Society.
[23] F. Diederich,et al. SYNTHESIS OF 1,2,4-TRISUBSTITUTED IMIDAZOLES AND 1,3,5-TRISUBSTITUTED 1,2,4-TRIAZOLES , 2008 .
[24] G. Klebe,et al. Studies Addressing the Importance of Charge in the Binding of Fosmidomycin‐Like Molecules to Deoxyxylulosephosphate Reductoisomerase , 2008, ChemMedChem.
[25] Luzi J. Barandun,et al. Inhibitors of the kinase IspE: structure-activity relationships and co-crystal structure analysis. , 2008, Organic & biomolecular chemistry.
[26] Murray N. Robertson,et al. Characterization of Aquifex aeolicus 4-diphosphocytidyl-2C-methyl-d-erythritol kinase – ligand recognition in a template for antimicrobial drug discovery , 2008, The FEBS journal.
[27] J. Wiesner,et al. Synthesis of β- and γ-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates , 2008 .
[28] F. Diederich,et al. Synthesis and Characterization of Cytidine Derivatives that Inhibit the Kinase IspE of the Non‐Mevalonate Pathway for Isoprenoid Biosynthesis , 2008, ChemMedChem.
[29] B. Kuhn,et al. Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis , 2008, J. Chem. Inf. Model..
[30] A. Djimde,et al. Monitoring and deterring drug-resistant malaria in the era of combination therapy. , 2007, The American journal of tropical medicine and hygiene.
[31] M. Machida,et al. Synthesis of thietane nucleosides by glycosidation of thietanose derivatives with nucleobases , 2007 .
[32] Ashley L. Ringer,et al. Models of S/π interactions in protein structures: Comparison of the H2S–benzene complex with PDB data , 2007, Protein science : a publication of the Protein Society.
[33] J. Wiesner,et al. Synthesis and evaluation of α,β-unsaturated α-aryl-substituted fosmidomycin analogues as DXR inhibitors , 2007 .
[34] William N. Hunter,et al. The Non-mevalonate Pathway of Isoprenoid Precursor Biosynthesis* , 2007, Journal of Biological Chemistry.
[35] F. Diederich,et al. Nonphosphate Inhibitors of IspE Protein, a Kinase in the Non‐Mevalonate Pathway for Isoprenoid Biosynthesis and a Potential Target for Antimalarial Therapy , 2007, ChemMedChem.
[36] F. Diederich,et al. Structure‐Based Design and Synthesis of the First Weak Non‐Phosphate Inhibitors for IspF, an Enzyme in the Non‐Mevalonate Pathway of Isoprenoid Biosynthesis , 2007 .
[37] D. Mann,et al. Using chemical genetics and ATP analogues to dissect protein kinase function. , 2007, ACS chemical biology.
[38] J. Wiesner,et al. Divergent strategy for the synthesis of α-aryl-substituted fosmidomycin analogues , 2007 .
[39] M. Egli,et al. Lone pair-aromatic interactions: to stabilize or not to stabilize. , 2007, Accounts of chemical research.
[40] B. Lell,et al. Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria , 2007, Antimicrobial Agents and Chemotherapy.
[41] L. Tong,et al. Crystal Structure of 1-Deoxy-d-xylulose 5-Phosphate Synthase, a Crucial Enzyme for Isoprenoids Biosynthesis* , 2007, Journal of Biological Chemistry.
[42] François Diederich,et al. Molekulare Erkennung von Phosphaten in der Strukturbiologie , 2007 .
[43] S. L. Macaulay,et al. A purine analog kinase inhibitor, calcium/calmodulin-dependent protein kinase II inhibitor 59, reveals a role for calcium/calmodulin-dependent protein kinase II in insulin-stimulated glucose transport. , 2007, Endocrinology.
[44] Markus Fischer,et al. Nonmevalonate terpene biosynthesis enzymes as antiinfective drug targets: substrate synthesis and high-throughput screening methods. , 2006, The Journal of organic chemistry.
[45] J. Wiesner,et al. Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria , 2006, Antimicrobial Agents and Chemotherapy.
[46] D. Grierson,et al. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. , 2006, Bioorganic & medicinal chemistry.
[47] L. McLaughlin,et al. Syntheses of pyridine C-nucleosides as analogues of the natural nucleosides dC and dU. , 2006, The Journal of organic chemistry.
[48] W. Eisenreich,et al. The crystal structure of a plant 2C‐methyl‐D‐erythritol 4‐phosphate cytidylyltransferase exhibits a distinct quaternary structure compared to bacterial homologues and a possible role in feedback regulation for cytidine monophosphate , 2006, The FEBS journal.
[49] A. Bacher,et al. Fluoreszierende Inhibitoren von IspF, einem Enzym im “Nicht‐Mevalonat‐Biosyntheseweg” der Isoprenoide und möglichen Ziel einer Antimalariatherapie , 2006 .
[50] Xiaodong Zhang,et al. 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. , 2005, Journal of medicinal chemistry.
[51] Roland Lange,et al. The crystal structure of E.coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in a ternary complex with the antimalarial compound fosmidomycin and NADPH reveals a tight-binding closed enzyme conformation. , 2005, Journal of molecular biology.
[52] Dong Hoon Kim,et al. A new synthetic analogue of thymidine, 7-(3-bromo-phenoxy)-thymidine, inhibits the proliferation of tumor cells. , 2005, Bioorganic & medicinal chemistry letters.
[53] François Diederich,et al. Wechselwirkungen mit aromatischen Ringen in chemischen und biologischen Erkennungsprozessen , 2003 .
[54] S. Yokoyama,et al. Crystal Structure of 4-(Cytidine 5′-diphospho)-2-C-methyl-d-erythritol kinase, an Enzyme in the Non-mevalonate Pathway of Isoprenoid Synthesis* , 2003, Journal of Biological Chemistry.
[55] W. Eisenreich,et al. Biosynthesis of isoprenoids: Crystal structure of 4-diphosphocytidyl-2C-methyl-d-erythritol kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Manoharan,et al. Structural Basis for Recognition of Guanosine by a Synthetic Tricyclic Cytosine Analogue: Guanidinium G-Clamp , 2003 .
[57] Shunsuke Yajima,et al. Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase complexed with cofactors: implications of a flexible loop movement upon substrate binding. , 2002, Journal of biochemistry.
[58] Gerhard Klebe,et al. Crystal Structure of 1-Deoxy-d-xylulose-5-phosphate Reductoisomerase, a Crucial Enzyme in the Non-mevalonate Pathway of Isoprenoid Biosynthesis* , 2002, The Journal of Biological Chemistry.
[59] S. Steinbacher,et al. Structure of 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids. , 2002, Journal of molecular biology.
[60] Peter A. Jones,et al. The Role of DNA Methylation in Mammalian Epigenetics , 2001, Science.
[61] D. Cane,et al. Structure of 4-diphosphocytidyl-2-C- methylerythritol synthetase involved in mevalonate- independent isoprenoid biosynthesis , 2001, Nature Structural Biology.
[62] E. De Clercq,et al. SYNTHESIS OF 1-(2-DEOXY-β-D-RIBOFURANOSYL)-2,4-DIFLUORO-5-SUBSTITUTED-BENZENES*: “THYMINE REPLACEMENT” ANALOGS OF THYMIDINE FOR EVALUATION AS ANTICANCER AND ANTIVIRAL AGENTS , 2001, Nucleosides, nucleotides & nucleic acids.
[63] H. Lichtenthaler,et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.
[64] Paul R. Gerber,et al. Charge distribution from a simple molecular orbital type calculation and non-bonding interaction terms in the force field MAB , 1998, J. Comput. Aided Mol. Des..
[65] Paul R. Gerber,et al. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..
[66] G. Arnett,et al. Carbocyclic analogues of 5-halocytosine nucleosides. , 1986, Journal of medicinal chemistry.
[67] T. Lincoln,et al. ATP analog specificity of cAMP-dependent protein kinase, cGMP-dependent protein kinase, and phosphorylase kinase. , 1984, European journal of biochemistry.
[68] A. Matsuda,et al. Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships. , 1983, Journal of medicinal chemistry.
[69] H. Vorbrüggen,et al. Nucleoside syntheses, XXII1) Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts , 1981 .
[70] G. Fronza,et al. NMR study of four-membered rings. VI. 1H spectra and conformation of thietane-l-oxide and thietane-1,1-dioxide , 1974 .
[71] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.